US Patent Issued to Terns Pharmaceuticals on Oct. 28 for "(r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[dimidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias" (California Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,454,524, issued on Oct. 28, was assigned to Terns Pharmaceuticals Inc. (Foster City, Calif.).

"(r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[dimidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias" was invented by F. Anthony Romero (Redwood City, Calif.), Thorsten A. Kirschberg (San Carlos, Calif.), Randall Halcomb (Foster City, Calif.) and Yingzi Xu (Palo Alto, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compounds, preferably (R)-N-(4-(chlorodifluoromethoxy) phenyl)-2-(difluoromethyl)-1-(1-hydroxypr...